RetinAI will attend AAO 2022 & is excited to introduce advances in AI for GA analysis & Progression Prediction & Discovery CORE™

Latest press releases

RetinAI receives FDA Clearance for Discovery, our medical image & data management platform for Ophthalmology

RetinAI today announces U.S. Food and Drug Administration (FDA) 510(k) clearance of RetinAI Discovery®, the company’s image and data management platform for next-level interoperability across the clinical and clinical study ecosystems in Ophthalmology.

RetinAI attends ARVO 2022

RetinAI will attend the ARVO 2022 Annual Meeting in Denver, Colorado, from May 1st to 4th at the Colorado Convention Center. RetinAI will showcase its innovative data management and AI analysis solutions to optimize and simplify clinical development workflows for stakeholders in pharma, research and clinics. ARVO attendees who visit RetinAI at Booth #3008 will benefit from learning and seeing live demos on RetinAI Discovery for clinical studies, Discovery UNITY and RetinAI's Disease Evaluation Apps.

RetinAI highlights Geographic Atrophy research with models available for analysis to enable the right decision sooner during clinical studies

RetinAI is pleased to share research findings from three published papers in Geographic Atrophy (GA). In collaboration with the Department of Ophthalmology at the University of Lausanne, Jules-Gonin Hospital, researchers at RetinAI developed a model for predicting atrophy risk in patients with non-exudative age-related macular degeneration (AMD).

RetinAI announces a collaboration with Isarna Therapeutics

RetinAI Medical AG announced a collaboration with Isarna Therapeutics under which RetinAI’s IT solutions and artificial intelligence tools, including RetinAI Discovery®, shall be employed to support The BETTER Study, an international clinical trial evaluating the efficacy of ISTH0036 for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).

Latest updates

Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography - Scientific Reports

RetinAI is thrilled to introduce our novel method for the segmentation of atrophy with performance matching human experts published in Scientific Reports and developed in collaboration with the Fondation Asile des aveugles, Hôpital ophtalmique Jules-Gonin in Lausanne. Congratulations to both teams for this success!

Full Article -

Authors: Yasmine Derradji, Agata Mosinska, Stefanos Apostolopoulos, Carlos Ciller, Sandro De Zanet & Irmela Mantel Widmer

Automatic Atrophy Progression Prediction in Age-Related Macular Degeneration in EURETINA 2021

We are happy to present our novel method for prediction of continuous atrophy growth for follow-up periods of 4 years and longer in this year's EURETINA 2021. Congratulations to our collaborators and team members for this great poster.

We enable for the first time the creation of atrophy risk maps, which present the risk of retinal regions being affected by the atrophy in the future.

Authors: Agata Mosinska, Anthony Gigon, Stefanos Apostolopoulos, Carlos Ciller, Irmela Mantel Widmer, Sandro De Zanet

RetinAI in Top 100 Swiss Startups for 2021

RetinAI is proud to be recognized as one of the TOP 100 Swiss Startups for 2021. Check out the ‘Hall of Fame’ on to see Retinai again in the list this year.

Huge thanks to everyone in the team, to our supporters, and to our partners for believing in us along the way and for supporting us to define the future of Digital Precision Medicine!

First Peer-reviewed Publication around the RAZORBILL Study

The very first peer-reviewed publication around the RAZORBILL study has been published in the British journal of Ophthalmology (BJO).

'Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study'

A first of its class international multi-center clinical study to assess the influence of automated 3D OCT scan enrichment with segmentation information on disease activity assessment in patients with nAMD treated with either brolucizumab, ranibizumab or aflibercept.

We are glad to be supporting this initiative together with a leading team of world renown ophthalmologists & Novartis!

Contact us for more informations! We are happy to hear from you!